Glutamate and the biology of gliomas

GLIA

Volumn 59, Issue 8, 2011, Pages 1181-1189

  de Groot, John ^a   Sontheimer, Harald ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Glioma; Growth; Invasion

Indexed keywords

AMPA RECEPTOR; FOCAL ADHESION KINASE; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTATHIONE; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SALAZOSULFAPYRIDINE; TALAMPANEL; TEMOZOLOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG ACTIVITY; DRUG METABOLISM; DRUG SAFETY; EXCITOTOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SEIZURE;

ANIMALS; BENZODIAZEPINES; BRAIN; BRAIN NEOPLASMS; GLIOMA; GLUTAMIC ACID; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, AMPA; SIGNAL TRANSDUCTION;

EID: 79957897718     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21113     Document Type: Article

References (81)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD. 2009. Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs 18: 1061-1083.
2. Allen NJ, Karadottir R, Attwell D. 2004. Reversal or reduction of glutamate and GABA transport in CNS pathology and therapy. Pflugers Arch 449: 132-142.
3. Arcella A, Carpinelli G, Battaglia G, D'Onofrio M, Santoro F, Ngomba RT, Bruno V, Casolini P, Giangaspero F, Nicoletti F. 2005. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 7: 236-245.
4. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D. 2003. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: Opposite regulation of glutamate transporter proteins. Eur J Neurosci 17: 2106-2118.
5. Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J. 2000. Extracellular glutamate and other metabolites in and around RG2 rat glioma: An intracerebral microdialysis study. J Neurooncol 47: 11-22.
6. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, Galli R, Passafaro M. 2009. The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells. Eur J Neurosci 30: 25-34.
7. Besson A, Yong VW. 2001. Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. J Neurooncol 51: 245-264.
8. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
9. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. [Review]. Neuron 1: 623-634.
10. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H. 2005. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25: 7101-7110.
11. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K. 2010. A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49-57.
12. Condorelli DF, Dell'Albani P, Corsaro M, Giuffrida R, Caruso A, Trovato SA, Spinella F, Nicoletti F, Albanese V, Giuffrida Stella AM. 1997. Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas. Neurochem Res 22: 1127-1133.
13. Contestabile A. 2000. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev 32: 476-509.
14. Danbolt NC. 2001. Glutamate uptake. Prog Neurobiol 65: 1-105.
15. da Rocha AB, Mans DR, Regner A, Schwartsmann G. 2002. Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas? Oncologist 7: 17-33.
16. de Groot JF, Liu TJ, Fuller G, Yung WK. 2005. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65: 1934-1940.
17. de Groot J, Milano V. 2009. Improving the prognosis for patients with glioblastoma: The rationale for targeting Src. J Neurooncol 95: 151-163.
18. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK. 2008. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88: 121-133.
19. Dzubay JA, Jahr CE. 1999. The concentration of synaptically released glutamate outside of the climbing fiber-purkinje cell synaptic cleft. JNeurosci 19: 5265-5274.
20. Estrela JM, Ortega A, Obrador E. 2006. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181.
21. Fan G, Sun B, Wu Z, Guo Q, Guo Y. 2004. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 59: 77-85.
22. Ferraguti F, Corti C, Valerio E, Mion S, Xuereb J. 2001. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp Brain Res 137: 1-11.
23. Goudar RK, Keir ST, Bigner DD, Friedman HS. 2004. NMDA and AMPA glutamate receptor antagonists in the treatment of human malignant glioma xenografts. AACR Meeting Abstracts 2004: 1053-105d.
24. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA. 2009. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial. J Clin Oncol 27: 4155-4161.
25. Guo H, Lai L, Butchbach ME, Lin CL. 2002. Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death. Mol Cell Neurosci 21: 546-560.
26. Harris LM, Davies NP, Macpherson L, Lateef S, Natarajan K, Brundler MA, Sgouros S, English MW, Arvanitis TN, Grundy RG, Peet AC. 2008. Magnetic resonance spectroscopy in the assessment of pilocytic astrocytomas. Eur J Cancer 44: 2640-2647.
27. Hayashi T, Umemori H, Mishina M, Yamamoto T. 1999. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397: 72-76.
28. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M, Sasaki T, Ozawa S. 2002. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8: 971-978.
29. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, Watanabe T, Saito N, Tsuzuki K, Okado H, Miwa A, Nakazato Y, Ozawa S. 2007. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27: 7987-8001.
30. Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. 2010. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 116: 1776-1782.
31. Kandil S, Brennan L, McBean GJ. 2010. Glutathione depletion causes a JNK and p38MAPK-mediated increase in expression of cystathionine-gamma-lyase and upregulation of the transsulfuration pathway in C6 glioma cells. Neurochem Int 56: 611-619.
32. Kim JY, Kanai Y, Chairoungdua A, Cha SH, Matsuo H, Kim DK, Inatomi J, Sawa H, Ida Y, Endou H. 2001. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta 1512: 335-344.
33. Kimelberg HK, Goderie SK, Higman S, Pang S, Waniewski RA. 1990. Swelling-induced release of glutamate, aspartate, and taurine from astrocyte cultures. J Neurosci 10: 1583-1591.
34. Knobbe CB, Merlo A, Reifenberger G. 2002. Pten signaling in gliomas. Neuro Oncol 4: 196-211.
35. Komuro H, Rakic P. 1993. Modulation of neuronal migration by NMDA receptors. Science 260: 95-97.
36. Lenz G, Avruch J. 2005. Glutamatergic regulation of the pZ0S6 kinase in primary mouse neurons. J Biol Chem 280: 38121-38124.
37. Lipton SA. 2004. Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1: 101-110.
38. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. 2007. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67: 9463-9471.
39. Malinow R, Malenka RC. 2002. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103-126.
40. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. 2010. In vivo assessment of high-grade glioma biochemistry using microdialysis: A study of energy-related molecules, growth factors and cytokines. J Neurooncol 97: 11-23.
41. Montana V, Malarkey EB, Verderio C, Matteoli M, Parpura V. 2006. Vesicular transmitter release from astrocytes. Glia 54: 700-715.
42. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. 1995. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52: 717-724.
43. Newton HB. 2003. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. I. Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3: 595-614.
44. Nguyen L, Rigo JM, Rocher V, Belachew S, Malgrange B, Rogister B, Leprince P, Moonen G. 2001. Neurotransmitters as early signals for central nervous system development. Cell Tissue Res 305: 187-202.
45. Nicholls D, Attwell D. 1990. The release and uptake of excitatory amino acids [see comments]. TIPS 11: 462-468.
46. Ohgaki H, Kleihues P. 2009. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
47. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. 1993. Vulnerability of oligodendroglia to glutamate: Pharamacology, mechanisms, and prevention. J Neurosci 13: 1441-1453.
48. Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, Haydon PG, Coulter DA. 2010. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci 13: 584-591.
49. Patel SA, Warren BA, Rhoderick JF, Bridges RJ. 2004. Differentiation of substrate and non-substrate inhibitors of transport system xc(-): An obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46: 273-284.
50. Piao Y, Lu L, de Groot J. 2009. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol 11: 260-273.
51. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. 2003. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901.
52. Reddy KB, Nabha SM, Atanaskova N. 2003. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403.
53. Rijpkema M, Schuuring J, van der MY, van der GM, Bernsen H, Boerman R, van der KA, Heerschap A. 2003. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 16: 12-18.
54. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, Black PM, Bours V. 2004. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10: 5595-5603.
55. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V. 2009. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9: 372.
56. Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT. 2003. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61: 151-160.
57. Rothstein JD. 2002. Paving new pathways. Nat Med 8: 938-940.
58. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes HM, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
59. Rzeski W, Turski L, Ikonomidou C. 2001. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98: 6372-6377.
60. Sato H, Tamba M, Ishii T, Bannai S. 1999. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274: 11455-11458.
61. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyupoglu IY. 2008. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14: 629-632.
62. Schenk U, Menna E, Kim T, Passafaro M, Chang S, De Camilli P, Matteoli M. 2005. A novel pathway for presynaptic mitogen-activated kinase activation via AMPA receptors. J Neurosci 25: 1654-1663.
63. Schousboe A, Westergaard N, Hertz L. 1993. Neuronal-astrocytic interactions in glutamate metabolism. Biochem Soc Trans 21: 49-53.
64. Schunemann DP, Grivicich I, Regner A, Leal LF, de Araujo DR, Jotz GP, Fedrigo CA, Simon D, da Rocha AB. 2010. Glutamate promotes cell growth by EGFR signaling on U-87MG human glioblastoma cell line. Pathol Oncol Res 16: 285-293.
65. Seifert G, Steinhauser C. 2001. Ionotropic glutamate receptors in astrocytes. Prog Brain Res 132: 287-299.
66. Sontheimer H. 2003. Malignant gliomas: Perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 26: 543-549.
67. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L, Ikonomidou C. 2009. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132: 435-445.
68. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Buhrer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C. 2005. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102: 15605-15610.
69. Szeliga M, Matyja E, Obara M, Grajkowska W, Czernicki T, Albrecht J. 2008. Relative expression of mRNAS coding for glutaminase isoforms in CNS tissues and CNS tumors. Neurochem Res 33: 808-813.
70. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. 2001. Glutamate release promotes growth of malignant gliomas. Nat Med 7: 1010-1015.
71. Thomas GM, Huganir RL. 2004. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5: 173-183.
72. Ulas J, Satou T, Ivins KJ, Kesslak JP, Cotman CW, Balazs R. 2000. Expression of metabotropic glutamate receptor 5 is increased in astrocytes after kainate-induced epileptic seizures. Glia 30: 352-361.
73. Vanhoutte N, Abarca-Quinones J, Jordan BF, Gallez B, Maloteaux JM, Hermans E. 2009. Enhanced expression of the high affinity glutamate transporter GLT-1 in C6 glioma cells delays tumour progression in rat. Exp Neurol 218: 56-63.
74. Wang Y, Durkin JP. 1995. alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, but not N-methyl-D-aspartate, activates mitogen-activated protein kinase through G-protein beta gamma subunits in rat cortical neurons. J Biol Chem 270: 22783-22787.
75. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. 2008. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 3: e3769.
76. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787.
77. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. 2009. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69: 7986-7993.
78. Ye ZC, Rothstein JD, Sontheimer H. 1999. Compromised glutamate transport in human glioma cells: Reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19: 10767-10777.
79. Ye ZC, Sontheimer H. 1999a. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59: 4383-4391.
80. Ye ZC, Sontheimer H. 1999b. Metabotropic glutamate receptor agonists reduce glutamate release from cultured astrocytes [In Process Citation]. Glia 25: 270-281.
81. Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR. 2003. Functional hemichannels in astrocytes: A novel mechanism of glutamate release. J Neurosci 23: 3588-3596.